143 related articles for article (PubMed ID: 35311091)
1. The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.
Sang YB; Kim JH; Kim CG; Hong MH; Kim HR; Cho BC; Lim SM
Front Oncol; 2022; 12():811247. PubMed ID: 35311091
[TBL] [Abstract][Full Text] [Related]
2. Function of Axl receptor tyrosine kinase in non-small cell lung cancer.
Zhang G; Wang M; Zhao H; Cui W
Oncol Lett; 2018 Mar; 15(3):2726-2734. PubMed ID: 29434997
[TBL] [Abstract][Full Text] [Related]
3. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications.
Wium M; Ajayi-Smith AF; Paccez JD; Zerbini LF
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806258
[TBL] [Abstract][Full Text] [Related]
4. AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Okimoto RA; Bivona TG
Lung Cancer (Auckl); 2015; 6():27-34. PubMed ID: 28210148
[TBL] [Abstract][Full Text] [Related]
5. AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew.
Auyez A; Sayan AE; Kriajevska M; Tulchinsky E
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638349
[TBL] [Abstract][Full Text] [Related]
6. AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.
Yan S; Vandewalle N; De Beule N; Faict S; Maes K; De Bruyne E; Menu E; Vanderkerken K; De Veirman K
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31694201
[TBL] [Abstract][Full Text] [Related]
7. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
Yang YM; Jang Y; Lee SH; Kang B; Lim SM
Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387
[TBL] [Abstract][Full Text] [Related]
8. Targeting AXL in NSCLC.
Zaman A; Bivona TG
Lung Cancer (Auckl); 2021; 12():67-79. PubMed ID: 34408519
[TBL] [Abstract][Full Text] [Related]
9. G-749 Promotes Receptor Tyrosine Kinase TYRO3 Degradation and Induces Apoptosis in Both Colon Cancer Cell Lines and Xenograft Mouse Models.
Kim HD; Park EJ; Choi EK; Song SY; Hoe KL; Kim DU
Front Pharmacol; 2021; 12():730241. PubMed ID: 34721022
[TBL] [Abstract][Full Text] [Related]
10. AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.
Lotsberg ML; Wnuk-Lipinska K; Terry S; Tan TZ; Lu N; Trachsel-Moncho L; Røsland GV; Siraji MI; Hellesøy M; Rayford A; Jacobsen K; Ditzel HJ; Vintermyr OK; Bivona TG; Minna J; Brekken RA; Baguley B; Micklem D; Akslen LA; Gausdal G; Simonsen A; Thiery JP; Chouaib S; Lorens JB; Engelsen AST
J Thorac Oncol; 2020 Jun; 15(6):973-999. PubMed ID: 32018052
[TBL] [Abstract][Full Text] [Related]
11. Targeting MERTK and AXL in
Yan D; Earp HS; DeRyckere D; Graham DK
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830794
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.
Lee W; Kim DK; Synn CB; Lee HK; Park S; Jung DS; Choi Y; Kim JH; Byeon Y; Kim YS; Lee S; Lee S; Joo Y; Lee EJ; Yun MR; Heo SG; Yang W; Jung JE; Kim EK; Park J; Park JD; Lee DJ; Kim HW; Lim SM; Hong MH; Ahn BC; Lee JB; Pyo KH
Front Oncol; 2022; 12():821391. PubMed ID: 35356198
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors.
Chung SH; Park J; Lee JW; Song J; Jung D; Min KH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1822-1833. PubMed ID: 32972253
[TBL] [Abstract][Full Text] [Related]
14. AXL as a Target in Breast Cancer Therapy.
Colavito SA
J Oncol; 2020; 2020():5291952. PubMed ID: 32148495
[TBL] [Abstract][Full Text] [Related]
15. Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response.
Davra V; Kimani SG; Calianese D; Birge RB
Cancers (Basel); 2016 Nov; 8(12):. PubMed ID: 27916840
[TBL] [Abstract][Full Text] [Related]
16. Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
Park K; Chang GC; Curigliano G; Lim WT; Soo RA; Molina-Vila MA; Cattan V; Darville H; Gandossi E; Smutna V; Sudey I; Viteri S
Lung Cancer; 2021 May; 155():127-135. PubMed ID: 33798902
[TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.
Smart SK; Vasileiadi E; Wang X; DeRyckere D; Graham DK
Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30501104
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment.
Wang KH; Ding DC
Tzu Chi Med J; 2021; 33(3):250-256. PubMed ID: 34386362
[TBL] [Abstract][Full Text] [Related]
19. The Receptor Tyrosine Kinase AXL in Cancer Progression.
Rankin EB; Giaccia AJ
Cancers (Basel); 2016 Nov; 8(11):. PubMed ID: 27834845
[TBL] [Abstract][Full Text] [Related]
20. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
